4.7 Article

Incidence of Pituitary Adenomas in Northern Finland in 1992-2007

期刊

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 95, 期 9, 页码 4268-4275

出版社

OXFORD UNIV PRESS INC
DOI: 10.1210/jc.2010-0537

关键词

-

向作者/读者索取更多资源

Context: Data on the incidence of pituitary adenomas (PAs) are scant and outdated. A population-based regional cohort with thorough case identification was used to evaluate the incidence of clinically detected PAs in the era of magnetic resonance imaging. Objective: The objective of the study was to describe the age-and sex-specific incidence of all PA subgroups, with data on incidentally found PAs, pituitary apoplexies, and time trends. Design, Settings, and Patients: This was a retrospective descriptive analysis of PA patients diagnosed during 1992-2007 in Northern Finland (NFi). Main Outcome Measure: World Health Organization 2000-standardized incidence rates (SIRs) of PAs per 100,000 were measured. Results and Conclusion: The final cohort consisted of 355 PAs. The incidence rates of the Oulu University Hospital regional district were used as a reference to assess the applicability of our case finding over the rest of NFi. Incidence rates of all PA subgroups except microprolactinomas were statistically equal between these areas; thus, all presented SIRs are based on the NFi's cohort except Oulu University Hospital regional district-based prolactinomas and PAs overall. Overall SIR of PAs was higher (4.0 per 100,000) than in previous reports. Prolactinomas had the highest SIR: 2.2 per 100,000, followed by clinically nonfunctioning PAs (1.0) and GH-secreting (0.34), ACTH-secreting (0.17), and TSH-secreting (0.03) PAs. The gender-specific SIR was 2.2 per 100,000 in males and 5.9 per 100,000 in females. Pituitary apoplexy occurred as a presenting symptom in 11% of clinically nonfunctioning PA patients. The SIR of incidentally discovered PAs increased significantly from 1992-1999 to 2000-2007 (0.59 to 1.6, respectively; P < 0.01), which accounted for the perceived increasing trend in the overall SIR of PAs (3.8 to 4.2; P > 0.05). (J Clin Endocrinol Metab 95: 4268-4275, 2010)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据